You can't find CPXX(Celator Pharmaceuticals) because it was bought out by Jazz Pharmaceuticals(JAZZ) in July of this year for $1.5 billion(US). They paid $30.25 per share for the 43 million shares of CPXX. The purchase was based on one drug called Vyxeos...
"On Tuesday, Jazz did not provide any sales forecasts for Vyxeos but previously, Celator has said the drug could achieve U.S. and European Vyxeos sales in the range of $200-270 million based on the subset of AML patients enrolled in the phase III study. If use of Vyxeos is expanded into other AML patient populations, peak sales could reach $690 million to $780 million, according to Celator."
CPXX had far more shares outstanding than HTBX and a drug which could in no way be compared to the Heat platform which will probably cover 30+ cancer and viral indications(multi-billions in market potential).
News 
Market Data 
Discover 
